Drugs / IFN α Kinoid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01058343 | Mar 2010 → Apr 2011 | systemic lupus erythematosus | Neovacs | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN α Kinoid | “IFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein.” PMID 27354683 ↗ Jun 2016 |
| Known as | IFN-K | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01058343 ↗ |
| Modality | Vaccine | “IFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein.” PMID 27354683 ↗ Jun 2016 |
| Route | Intramuscular | “3 to 4 IM injections over 3 months” NCT01058343 ↗ |